Powered by Translate

Cyclohexanone

General Description

  • Synonyms: Anone; Pimelic ketone; Cyclohexyl ketone; Ketohexamethylene
  • OSHA IMIS Code Number: 0830
  • Chemical Abstracts Service (CAS) Registry Number: 108-94-1
  • NIOSH Registry of Toxic Effects of Chemical Substances (RTECS) Identification Number: GW1050000
  • Department of Transportation Regulation Number (49 CFR 172.101) and Emergency Response Guidebook: 1915 127
  • NIOSH Pocket Guide to Chemical Hazards, Cyclohexanone: chemical description, physical properties, potentially hazardous incompatibilities, and more

Exposure Limits

  • OSHA Permissible Exposure Limit (PEL):
  • American Conference of Governmental Industrial Hygienists (ACGIH) Threshold Limit Value (TLV): 20 ppm, 80 mg/m3 TWA; 50 ppm, 200 mg/m3 STEL; Skin; Appendix A3 - Confirmed Animal Carcinogen with Unknown Relevance to Humans
  • National Institute for Occupational Safety and Health (NIOSH) Recommended Exposure Limit (REL): 25 ppm, 100 mg/m3 TWA; Skin

Health Factors

NIOSH Immediately Dangerous To Life or Health Concentration (IDLH): 700 ppm

  • Potential Symptoms: Irritation of eyes, skin, mucous membrane; headache; narcosis; coma; dermatitis; in animals: liver, kidney damage
  • Health Effects: Irritation-Eye, Nose, Throat, Skin---Moderate (HE15); Cumulative liver and kidney damage (HE3); Narcosis (HE8)
  • Affected Organs: Eyes, skin, respiratory system, CNS, liver, kidneys
  • Notes:
  1. Above 44ºC, explosive vapor/air mixtures may be formed.
  2. EPA's oral reference dose (daily oral exposure likely to be without an appreciable risk of deleterious effects during a lifetime) for cyclohexanone is 5 mg/kg/day.
  3. Two cases of contact dermatitis due to cyclohexanone exposure have been reported.
  4. In a study with human volunteers who inhaled cyclohexanone for 8 hours, the major urinary metabolites over 72 hours were found to be 1,2-cyclohexanediol (38-41% of dose) and 1,4-cyclohexanediol (18-21% of dose), including their glucuronide conjugates. These metabolites appeared to be useful for biomonitoring exposure to cyclohexanone.

Literature Basis:

  • NIOSH Pocket Guide to Chemical Hazards: Cyclohexanone.
  • International Chemical Safety Cards (WHO/IPCS/ILO): Cyclohexanone.
  • U.S. EPA Integrated Risk Information System: Cyclohexanone (CASRN 108-94-1).
  • Mráz, J., Gálová, E., Nohová, H. and Vítková, D.: Uptake, metabolism and elimination of cyclohexanone in humans. Int. Arch. Occup. Environ. Health 66(3): 203-208, 1994.
  • Pazzaglio, M., Tullo, S., Voudouris, S. and Tosti, A.: Contact dermatitis due to cyclohexanone: a further case. Contact Dermatitis 49(6): 313, 2003.
  • Pohanish, R.P. (editor): Cyclohexanone. In, Sittig's Handbook of Toxic and Hazardous Chemicals and Carcinogens, Fourth Ed., Vol. 1. Norwich, NY: Noyes Publications, William Andrew Publishing, 2002, pp. 719-721.

Date Last Revised: 05/05/2006

Monitoring Methods used by OSHA

Primary Laboratory Sampling/Analytical Method (SLC1):
  • Chromosorb 106 Tube (100/50 sections, 60/80 mesh)
  • analytical solvent: Carbon Disulfide
  • maximum volume: 10 Liters
  • maximum flow rate: 0.2 L/min
  • current analytical method: Gas Chromatography; GC/FID
  • method reference: OSHA Analytical Method (OSHA 1)
  • method classification: Fully Validated

** All Trademarks are the property of their respective owners.

Index

By Name

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

By CAS Number
collage image - OSHA Salt Lake Technical Center
Back to Top

Thank You for Visiting Our Website

You are exiting the Department of Labor's Web server.

The Department of Labor does not endorse, takes no responsibility for, and exercises no control over the linked organization or its views, or contents, nor does it vouch for the accuracy or accessibility of the information contained on the destination server. The Department of Labor also cannot authorize the use of copyrighted materials contained in linked Web sites. Users must request such authorization from the sponsor of the linked Web site. Thank you for visiting our site. Please click the button below to continue.

Close